Published October 1, 2011 | Version v1
Journal article

Targeting the erythropoietin receptor on glioma cells reduces tumour growth

  • 1. CERVOxy team 'Hypoxia and cerebrovascular pathophysiology', UMR 6232 CI-NAPS, Universite de Caen Basse-Normandie, Universite Paris-Descartes, CNRS, CEA. G.I.P. CYCERON, Caen (France)
  • 2. Departement de Neurologie, CHU de Caen (France)
  • 3. Service d'Histologie-Biologie Tumorale, ER2UPMC, Universite Paris 6, Hopital Tenon, Paris (France)
  • 4. Service d'Anatomie Pathologique, CHU de Caen (France)

Description

Hypoxia has been shown to be one of the major events involved in EPO expression. Accordingly, EPO might be expressed by cerebral neoplastic cells, especially in glioblastoma, known to be highly hypoxic tumours. The expression of EPOR has been described in glioma cells. However, data from the literature remain descriptive and controversial. On the basis of an endogenous source of EPO in the brain, we have focused on a potential role of EPOR in brain tumour growth. In the present study, with complementary approaches to target EPO/EPOR signalling, we demonstrate the presence of a functional EPO/EPOR system on glioma cells leading to the activation of the ERK pathway. This EPO/EPOR system is involved in glioma cell proliferation in vitro. In vivo, we show that the down-regulation of EPOR expression on glioma cells reduces tumour growth and enhances animal survival. Our results support the hypothesis that EPOR signalling in tumour cells is involved in the control of glioma growth.

Availability note (English)

Available from http://dx.doi.org/10.1016/j.yexcr.2011.06.011

Additional details

Identifiers

DOI
10.1016/j.yexcr.2011.06.011;
PII
S0014-4827(11)00247-3;

Publishing Information

Journal Title
Experimental Cell Research
Journal Volume
317
Journal Issue
16
Journal Page Range
p. 2321-2332
ISSN
0014-4827
CODEN
ECREAL

Optional Information

Copyright
Copyright (c) 2011 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.